MENU

Fox Chase Cancer Center News

April 18, 2022

Fox Chase Cancer Center Nurses Harness Electronic Medical Record Tool to Better Monitor Oral Chemotherapy Use

PHILADELPHIA (April 18, 2022)—Nurses at Fox Chase Cancer Center successfully implemented an electronic medical record tool to improve compliance documentation for patients taking oral chemotherapy drugs.

April 13, 2022

Cancer Study Group Launches Collaborative Patient Care Effort with Fox Chase Cancer Center

Philadelphia, PA and Washington, DC. (April 13, 2022) — Cancer Study Group, LLC, a company that works with employer and union health plans to guide their patients through cancer, is partnering with Fox Chase Cancer Center to provide patients fast, dedicated access to sub-specialized care.

April 4, 2022

Fox Chase Researchers Find Higher Levels of Estrogen Derivatives in Lung Cancer Patients Who Have Never Smoked

PHILADELPHIA (April 4, 2022)—Nonsmokers with the two most common types of driver-gene mutated lung cancer have higher levels of the estrogen derivative 4-OHE, according to early data from researchers at Fox Chase Cancer Center, which will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 on April 8-13, 2022.

April 4, 2022

Fox Chase Molecular Therapeutics Researchers to Present Findings From Recent Studies at AACR Annual Meeting

PHILADELPHIA (April 4, 2022)— During the American Association for Cancer Research (AACR) Annual Meeting 2022 on April 8-13, 2022, researchers from the lab of Philip Abbosh, MD, PhD, an assistant professor in the Molecular Therapeutics research program at Fox Chase Cancer Center, will present findings from recent studies.

April 4, 2022

Dr. Elizabeth Plimack Appointed Deputy Director at Fox Chase Cancer Center

PHILADELPHIA (April 4, 2022)—Elizabeth Plimack, MD, MS, chief of the Division of Genitourinary Medical Oncology and professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, has been appointed Deputy Director.

March 31, 2022

Newly Defined Renal Neoplasm Has Low Risk of Metastasis, So Patients May Be Able to Avoid Surgery

PHILADELPHIA (March 31, 2022)—Researchers at Fox Chase Cancer Center have published a new study that identifies several characteristics of papillary renal neoplasm with reverse polarity (PRNRP), a neoplasm that may simply be monitored rather than removing it through surgery.

March 30, 2022

Fox Chase Researchers Study Role of PP2A/B55α in Cellular Processes and Cancer Development

PHILADELPHIA (March 30, 2022)—In a recent study, researchers from Fox Chase Cancer Center have begun to define how PP2A/B55α recognizes its substrates, which are protein targets. The work may ultimately help the researchers identify other targets involved in cancer progression.

March 25, 2022

Fox Chase Researchers Study PTEN Mutations in Colorectal Cancer Patients to Enhance Clinical Targeting

PHILADELPHIA (March 25, 2022)—In a new study released today in the prestigious journal Nature Communications, researchers at Fox Chase Cancer Center who looked at over 34,000 colorectal cancer patients learned that certain PTEN mutations occur in distinct patterns in specific subsets of colorectal cancer. The finding could help clinicians administer available therapies to colorectal cancer patients in a more personalized way.

Pages

Connect with Fox Chase